Advertisement
Loading...

RHÖN-KLINIKUM AG

RHKJFPNK
Healthcare
Medical - Care Facilities
$15.30
$0.00(0.00%)
U.S. Market opens in 42h 13m
Advertisement

RHÖN-KLINIKUM AG Fundamental Analysis

RHÖN-KLINIKUM AG (RHKJF) shows weak financial fundamentals with a PE ratio of 21.88, profit margin of 2.32%, and ROE of 3.04%. The company generates $1.7B in annual revenue with weak year-over-year growth of -8.02%.

Key Strengths

Cash Position56.52%
PEG Ratio-3.96
Current Ratio2.57

Areas of Concern

ROE3.04%
Operating Margin2.83%
We analyze RHKJF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 25.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
25.9/100

We analyze RHKJF's fundamental strength across five key dimensions:

Efficiency Score

Weak

RHKJF struggles to generate sufficient returns from assets.

ROA > 10%
2.17%

Valuation Score

Excellent

RHKJF trades at attractive valuation levels.

PE < 25
21.88
PEG Ratio < 2
-3.96

Growth Score

Moderate

RHKJF shows steady but slowing expansion.

Revenue Growth > 5%
-8.02%
EPS Growth > 10%
12.07%

Financial Health Score

Excellent

RHKJF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.08
Current Ratio > 1
2.57

Profitability Score

Weak

RHKJF struggles to sustain strong margins.

ROE > 15%
3.04%
Net Margin ≥ 15%
2.32%
Positive Free Cash Flow
No

Key Financial Metrics

Is RHKJF Expensive or Cheap?

P/E Ratio

RHKJF trades at 21.88 times earnings. This indicates a fair valuation.

21.88

PEG Ratio

When adjusting for growth, RHKJF's PEG of -3.96 indicates potential undervaluation.

-3.96

Price to Book

The market values RHÖN-KLINIKUM AG at 0.66 times its book value. This may indicate undervaluation.

0.66

EV/EBITDA

Enterprise value stands at 7.88 times EBITDA. This is generally considered low.

7.88

How Well Does RHKJF Make Money?

Net Profit Margin

For every $100 in sales, RHÖN-KLINIKUM AG keeps $2.32 as profit after all expenses.

2.32%

Operating Margin

Core operations generate 2.83 in profit for every $100 in revenue, before interest and taxes.

2.83%

ROE

Management delivers $3.04 in profit for every $100 of shareholder equity.

3.04%

ROA

RHÖN-KLINIKUM AG generates $2.17 in profit for every $100 in assets, demonstrating efficient asset deployment.

2.17%

Following the Money - Real Cash Generation

Operating Cash Flow

RHÖN-KLINIKUM AG generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

RHÖN-KLINIKUM AG generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

RHKJF converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

21.88

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-3.96

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.66

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.51

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.57

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.03

vs 25 benchmark

ROA

Return on assets percentage

0.02

vs 25 benchmark

ROCE

Return on capital employed

0.03

vs 25 benchmark

How RHKJF Stacks Against Its Sector Peers

MetricRHKJF ValueSector AveragePerformance
P/E Ratio21.8829.38 Better (Cheaper)
ROE3.04%739.00% Weak
Net Margin2.32%-53619.00% (disorted) Weak
Debt/Equity0.080.39 Strong (Low Leverage)
Current Ratio2.574.03 Strong Liquidity
ROA2.17%-20116.00% (disorted) Weak

RHKJF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews RHÖN-KLINIKUM AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

22.37%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

0.17%

Industry Style: Defensive, Growth, Innovation

Growing

FCF CAGR

169.77%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ